Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Current concepts in coronary thrombolysis.

P R Eisenberg¹

¹Cardiovascular Division, Washington University School of Medicine, St. Louis, Missouri.

Hematology/Oncology Clinics of North America

|October 1, 1992

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Factor XII-dependent increases in thrombin activity induce carboxypeptidase-mediated attenuation of pharmacological fibrinolysis.

Journal of thrombosis and haemostasis : JTH·2004

Same author

Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from PURSUIT.

Circulation·2001

Same author

N-acetyl-cysteine reduces neointimal thickening and procoagulant activity after balloon-induced injury in abdominal aortae of New Zealand white rabbits.

Thrombosis and haemostasis·2001

Same author

Pathologic regression of primary pulmonary hypertension in left native lung following right single-lung transplantation.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2001

Same author

A novel synthetic inhibitor of factor Xa decreases early reocclusion and improves 24-h patency after coronary fibrinolysis in dogs.

The Journal of pharmacology and experimental therapeutics·2001

Same author

Thrombus determinants of vascular cell activation.

Italian heart journal : official journal of the Italian Federation of Cardiology·2000

Coronary thrombolysis success hinges on balancing clot-dissolving and clotting factors. New anticoagulants may improve outcomes, but clinical trials are needed to confirm safety and efficacy in preventing recurrent thrombosis.

Area of Science:

Cardiovascular Medicine
Hematology

Background:

Coronary thrombolysis efficacy is linked to a balance between fibrinolysis and procoagulant activity.
Plasminogen activators influence clot lysis rates, procoagulant activity, and platelet activation.
Recurrent thrombosis remains a challenge despite current treatments like aspirin and heparin.

Purpose of the Study:

To explore the role of fibrinolytic and procoagulant balance in coronary thrombolysis.
To assess the impact of plasminogen activators on thrombolytic outcomes.
To evaluate the potential of novel anticoagulants in improving treatment strategies.

Main Methods:

Review of current understanding of fibrinolytic and procoagulant dynamics.
Analysis of plasminogen activator properties and their effects.

Related Experiment Videos

Consideration of existing and emerging anticoagulant therapies.

Main Results:

Specific plasminogen activators differentially affect clot lysis, procoagulant activity, and platelet activation.
Current aspirin and heparin regimens reduce, but do not eliminate, recurrent thrombosis.
New anticoagulants offer diverse mechanisms for potentially enhanced therapeutic strategies.

Conclusions:

Achieving optimal coronary thrombolysis requires careful management of the fibrinolytic-procoagulant balance.
Further clinical trials are essential to validate the safety and survival benefits of newer anticoagulant agents in patients undergoing thrombolysis.